Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: February 9, 2023

Details for Patent: 6,602,911

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 6,602,911 protect, and when does it expire?

Patent 6,602,911 protects SAVELLA and is included in one NDA.

This patent has sixteen patent family members in nine countries.

Summary for Patent: 6,602,911

Title:	Methods of treating fibromyalgia
Abstract:	The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s):	Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee:	Cypress Bioscience, Inc. (San Diego, CA)
Application Number:	10/028,547
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,602,911
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 6,602,911

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Allergan	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-001	Jan 14, 2009		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				MANAGEMENT OF FIBROMYALGIA (FM)	See Plans and Pricing
Allergan	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-002	Jan 14, 2009		RX	Yes	No	See Plans and Pricing	See Plans and Pricing				MANAGEMENT OF FIBROMYALGIA (FM)	See Plans and Pricing
Allergan	SAVELLA	milnacipran hydrochloride	TABLET;ORAL	022256-003	Jan 14, 2009		RX	Yes	Yes	See Plans and Pricing	See Plans and Pricing				MANAGEMENT OF FIBROMYALGIA (FM)	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 6,602,911

Subscribe to access the full database, or Try it Free
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	552856	See Plans and Pricing
Australia	2003268020	See Plans and Pricing
Canada	2467356	See Plans and Pricing
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey

Merck

Mallinckrodt

Johnson and Johnson

Harvard Business School

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.